Özyiğit Leyla Pur, Öztürk Ayşe Bilge, Bavbek Sevim
Department of Pulmonary Disease, Division of Immunology and Allergy, Koç University School of Medicine, İstanbul, Turkey.
Department of Pulmonary Disease, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey.
Turk Thorac J. 2020 Jan;21(1):61-68. doi: 10.5152/TurkThoracJ.2019.180204. Epub 2020 Jan 1.
Improved knowledge about the pathogenesis of asthma has facilitated the development of novel drugs and provided hope for patients with severe asthma. After the short- and long-term success of omalizumab in severe allergic phenotype, researchers have targeted patients with severe eosinophilic asthma who comprise up to 45% of adult severe asthma. Interleukin (IL)-5 and IL-5 receptor subunit α play crucial roles in the development, maturation, and operation of eosinophils. Currently, patients treated with anti-IL-5 biologicals depleting eosinophils experience the positive efficacy of these drugs, especially with regard to the reduction of exacerbation rate. The aim of this review was to shed light on severe eosinophilic asthma treatment with these new currently available agents selectively targeting IL-5 or its receptor, discussing their usage including pre-treatment concerns, such as selecting the target population and choosing the right agent among them, and subsequent assessment of relevant effect and safety issues.
对哮喘发病机制的深入了解推动了新型药物的研发，并为重度哮喘患者带来了希望。在奥马珠单抗在重度过敏表型中取得短期和长期成功后，研究人员将目标对准了重度嗜酸性粒细胞性哮喘患者，这类患者占成年重度哮喘患者的比例高达45%。白细胞介素（IL）-5和IL-5受体亚基α在嗜酸性粒细胞的发育、成熟和运作中起关键作用。目前，接受抗IL-5生物制剂治疗以消耗嗜酸性粒细胞的患者体验到了这些药物的积极疗效，尤其是在降低急性加重率方面。本综述的目的是阐明使用这些目前可用的、选择性靶向IL-5或其受体的新型药物治疗重度嗜酸性粒细胞性哮喘的情况，讨论它们的用法，包括治疗前的注意事项，如选择目标人群以及在其中选择合适的药物，以及随后对相关疗效和安全性问题的评估。
